TORONTO, Feb. 20, 2018 -- Axiom Real-Time Metrics, the premier provider of eClinical solutions and services to small to mid-sized life sciences organizations, is exhibiting at Outsourcing in Clinical Trials West Coast 2018, February 21-22 in Burlingame, California.
“Axiom has an extensive client network on the west coast and we are excited to participate in events such as this, which connect us with leading edge companies to develop new relationships,” expressed Andrew Schachter, CEO and Founder. Axiom invites attendees to join our team for a conversation over coffee at Booth 25.
"Outsourcing is a critical element that must be well managed to achieve success in the life sciences industry, and we are very passionate about playing a key role in our client's technology needs. Our software solutions are relied upon daily by our clients, so their teams can effectively manage their studies, and get products to market faster. We collaborate closely with our clients to develop, design, and launch new features and functionalities that solve key problems. Our product road map includes many innovations that are unique to the market and significantly influenced by client input,” shared Heather Williams, Senior Director of Client Engagement.
Sarah Glofcheskie, Chief Strategy Officer further contributed, "We have deep expertise and excel in meeting the needs of small to mid-sized biotech, pharma, and device companies. We strongly believe that all organizations, irrespective of size, should be working with best-in-class, enterprise-level tools in terms of functionality. A fully unified platform is essential so that your data resides in one spot – it is critical to own your data relationship. Axiom Fusion enables single sign-on to all modules and associated data used in your studies. The ability to tailor a suite based on your needs is key - you choose exactly what you need from our 15 modules and complementary services. Please stop by our booth for a conversation. Our approach is different, and we'd like to show you how."
About Axiom Real-Time Metrics
Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: DM, Biostatistics and Pharmacovigilance. Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.
CONTACT INFORMATION
Contact
[email protected]
+1.877.321.9191
PR Contact
Sarah Glofcheskie
[email protected]
+1.647.588.9073


Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Shein Scales Back Vietnam Operations as US Trade Rules Shift
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 



